Clinical Trials
11 trialsNCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
NCT00516724 2025-04-11
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
AstraZeneca
Phase 1 Completed
NCT06062602 2023-10-06
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
Presage Biosciences
Phase EARLY_PHASE1 Completed
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT02659059 2023-04-05
CheckMate 568
Bristol-Myers Squibb
Phase 2 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT01160601 2017-04-19
Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer
Peregrine Pharmaceuticals
Phase 2 Completed
NCT00873119 2015-07-28
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Valerio Therapeutics
Phase 2 Completed
NCT00111007 2014-10-31
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 3 Completed
NCT00708812 2011-07-21
Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Phase 2 Completed
NCT00087802 2009-04-16
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 3 Completed